Integra Lifesciences Holdings Corp (NASDAQ:IART) price on Friday, April 11, fall -2.47% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $16.99.
A look at the stock’s price movement, the close in the last trading session was $17.42, moving within a range at $15.95 and $17.46. The beta value (5-Year monthly) was 1.245. Turning to its 52-week performance, $34.41 and $16.81 were the 52-week high and 52-week low respectively. Overall, IART moved -23.71% over the past month.
Integra Lifesciences Holdings Corp’s market cap currently stands at around $1.31 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-24.
Analysts have a consensus estimate of 381.17M for the company’s revenue for the quarter, with a low and high estimate of 379.29M and 385M respectively. The average forecast suggests up to a 3.33% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.68B, representing a 4.28% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IART is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 2 recommend IART as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IART’s current price about -19.16% and -24.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 27.21, while 7-day volatility ratio is 12.07% and 5.76% in the 30-day chart. Further, Integra Lifesciences Holdings Corp (IART) has a beta value of 1.30, and an average true range (ATR) of 1.31. Analysts have given the company’s stock an average 52-week price target of $33, forecast between a low of $20 and high of $86. Looking at the price targets, the low is -17.72% off current price level while to achieve the yearly target high, price needs to move -406.18%. Nonetheless, investors will most likely welcome a -94.23% jump to $33 which is the analysts’ median price.
If we refocus on Integra Lifesciences Holdings Corp (NASDAQ:IART), historical trading data shows that trading volumes averaged 0.69 over the past 10 days and 678.61K over the past 3 months. The company’s latest data on shares outstanding shows there are 77.17 million shares.
The 14.38% of Integra Lifesciences Holdings Corp’s shares are in the hands of company insiders while institutional holders own 90.47% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.98 million on 2025-03-14, giving us a short ratio of 4.64. The data shows that as of 2025-03-14 short interest in Integra Lifesciences Holdings Corp (IART) stood at 598.0 of shares outstanding, with shares short rising to 3.5 million registered in 2025-02-14. Current price change has pushed the stock -25.09% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IART stock continues to rise going into the next quarter.
